[go: up one dir, main page]

ECSP088505A - Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia - Google Patents

Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia

Info

Publication number
ECSP088505A
ECSP088505A EC2008008505A ECSP088505A ECSP088505A EC SP088505 A ECSP088505 A EC SP088505A EC 2008008505 A EC2008008505 A EC 2008008505A EC SP088505 A ECSP088505 A EC SP088505A EC SP088505 A ECSP088505 A EC SP088505A
Authority
EC
Ecuador
Prior art keywords
negative symptoms
antagonist
combination
chichophrenia
secondary effects
Prior art date
Application number
EC2008008505A
Other languages
English (en)
Inventor
Mark Black
Beth Borowsky
Nancy Rogacki
Yaw Senyah
Rachel Stevens
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ECSP088505A publication Critical patent/ECSP088505A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención describe y reivindica un método para tratar déficits cognitivos en un paciente que padece esquizofrenia, mediante la administración a dicho paciente de una cantidad terapéuticamente eficaz de un antagonista del receptor CB1 como se describe en esta memoria. En otro aspecto, esta invención también describe y reivindica una combinación de uno o más antagonistas del receptor CB1 y de uno o más agentes antipsicóticos útiles en el tratamiento de trastornos psiquiátricos. La combinación de esta invención proporciona resultados sinérgicos en los que la combinación mejora los síntomas positivos y negativos de la esquizofrenia, la ganancia de peso y la catalepsia.
EC2008008505A 2005-12-08 2008-06-06 Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia ECSP088505A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74843405P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
ECSP088505A true ECSP088505A (es) 2008-08-29

Family

ID=37964962

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008505A ECSP088505A (es) 2005-12-08 2008-06-06 Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia

Country Status (23)

Country Link
US (1) US20080221078A1 (es)
EP (1) EP1962834A2 (es)
JP (1) JP2009518423A (es)
KR (1) KR20080073737A (es)
CN (1) CN101321523A (es)
AR (1) AR056846A1 (es)
AU (1) AU2006321907A1 (es)
BR (1) BRPI0619541A2 (es)
CA (1) CA2632673A1 (es)
CR (1) CR9957A (es)
DO (1) DOP2006000273A (es)
EC (1) ECSP088505A (es)
IL (1) IL191888A0 (es)
MA (1) MA30090B1 (es)
NO (1) NO20082923L (es)
PE (1) PE20071092A1 (es)
RU (1) RU2008127491A (es)
SV (1) SV2008002929A (es)
TN (1) TNSN08205A1 (es)
TW (1) TW200803839A (es)
UY (1) UY29995A1 (es)
WO (1) WO2007067617A2 (es)
ZA (1) ZA200803924B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8304434B2 (en) * 2007-10-04 2012-11-06 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
PE20091270A1 (es) * 2007-12-18 2009-09-23 Sanofi Aventis Derivados de azetidinas con actividad sobre receptores cb1 y su preparacion
FR2925051B1 (fr) * 2007-12-18 2010-05-21 Sanofi Aventis Derives d'azetidines,leur preparation et leur application en therapeutique
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CN112961149A (zh) 2014-08-11 2021-06-15 安吉恩生物医药公司 细胞色素p450抑制剂及其用途
KR20230026515A (ko) * 2014-09-10 2023-02-24 에피자임, 인코포레이티드 Ｓｍｙｄ 억제제
EP3240778A4 (en) 2014-12-31 2018-07-11 Angion Biomedica Corp. Methods and agents for treating disease
FI3504187T3 (fi) 2016-08-24 2025-04-05 Prilenia Neurotherapeutics Ltd Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
KR20060019587A (ko) * 2003-06-11 2006-03-03 머크 앤드 캄파니 인코포레이티드 치환된 3-알킬 및 3-알케닐 아제티딘 유도체
RU2006110545A (ru) * 2003-09-02 2007-10-10 Зольвай Фармасьютикалз Гмбх (De) Новое медицинское применение избирательных антагонистов св1-рецептора
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique

Also Published As

Publication number Publication date
PE20071092A1 (es) 2007-12-10
CA2632673A1 (en) 2007-06-14
TNSN08205A1 (en) 2009-10-30
EP1962834A2 (en) 2008-09-03
UY29995A1 (es) 2007-07-31
CN101321523A (zh) 2008-12-10
AU2006321907A1 (en) 2007-06-14
AR056846A1 (es) 2007-10-24
CR9957A (es) 2008-09-22
NO20082923L (no) 2008-09-02
RU2008127491A (ru) 2010-01-20
WO2007067617A3 (en) 2007-11-01
KR20080073737A (ko) 2008-08-11
WO2007067617A2 (en) 2007-06-14
BRPI0619541A2 (pt) 2011-10-04
IL191888A0 (en) 2009-08-03
SV2008002929A (es) 2009-12-02
JP2009518423A (ja) 2009-05-07
DOP2006000273A (es) 2007-10-15
US20080221078A1 (en) 2008-09-11
TW200803839A (en) 2008-01-16
MA30090B1 (fr) 2008-12-01
ZA200803924B (en) 2009-10-28

Similar Documents

Publication Publication Date Title
ECSP088505A (es) Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
MX2021004708A (es) Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
ZA201903091B (en) Methods of treating inflammatory conditions
ATE477252T1 (de) Substituierte diazepane als antagonisten an orexinrezeptoren
UY31619A1 (es) Compuestos espiro como antagonistas del receptor npy y5
CR20140085A (es) Inhibidores de pde10 de pirimidina
CO6251266A2 (es) Antagonistas piridil piperidina del receptor de orexina
MX2009005712A (es) Antagonistas de receptor de orexina de diazepam sustituido.
MX2017005940A (es) Pyrazolo [1, 5-a] pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos.
GT200800265A (es) Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas.
CO6290684A2 (es) Inhibidores de actividad de proteina tirosina quinasa
ECSP088619A (es) Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
CO6300955A2 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina -3
ATE517106T1 (de) Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
UA106873C2 (uk) Сполуки заміщених діазепанів як антагоністи орексинових рецепторів
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
DE602006019304D1 (de) Spirohydantoin-aryl-cgrp-rezeptorantagonisten
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
GB2470495A (en) Oxazolidine derivatives as NMDA antagonists
EA201071119A1 (ru) Применение гетероциклических бензопроизводных сульфамида для лечения тревожных расстройств
ECSP14013268A (es) Inhibidores de pde10 de pirimidina
CL2011000234A1 (es) Compuestos derivados de ciclohexilamida sustituida, antagonista del receptor del factor de liberación de corticotropina (crf-1); composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento y/o prevencion de trastornos gastrointestinales, depresivos, esquizofrenia, parkinson, inflamacion, obesidad, entre otros.